Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Bahar Uncu Ulu, Mehmet Sinan Dal, İpek Yönal Hindilerden, Olga Meltem Akay, Özgür Mehtap, Nurhilal Büyükkurt, Fehmi Hindilerden, Ahmet Kürşad Güneş, Tuğçe Nur Yiğenoğlu, Semih Başcı, Merih Kızıl Çakar, Didar Yanardağ Açık, Serdal Korkmaz, Turgay Ulaş, Gülsüm Özet, Burhan Ferhanoğlu, Meliha Nalçacı & Fevzi Altuntaş. (2022) Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy 34:3, pages 190-198.
Read now
Read now
Terry K. Pak, Brianne N. Dixon, Michael J. Buege, Phuong H. Dao, Megan H. Leary, Joy C. Jarrett, Tara A. Duggan, Philip Caron, Lorenzo Falchi, Paul Hamlin, Audrey Hamilton, Matthew J. Matasar, Alison Moskowitz, Ariela Noy, Colette N. Owens, Gottfried Von Keudell, Anas Younes, Andrew D. Zelenetz & Anita Kumar. (2022) Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. Leukemia & Lymphoma 63:4, pages 876-884.
Read now
Read now
Bhupender S Chhikara & Keykavous Parang. (2010) Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opinion on Drug Delivery 7:12, pages 1399-1414.
Read now
Read now
Articles from other publishers (28)
Nasrullah Jan, Hassan Shah, Safiullah Khan, Faiza Nasar, Asadullah Madni, Syed Faisal Badshah, Ahsan Ali & Mohammad F. Bostanudin. (2023) Old drug, new tricks: polymer-based nanoscale systems for effective cytarabine delivery. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Kanta Devi, Salman Muhammad Soomar, Muhammad Usman Shaikh & Natasha Ali. (2023) Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma. Annals of Medicine & Surgery 85:9, pages 4256-4261.
Crossref
Crossref
Alnecia R Nisbett, Xiaoqin Yang, Patrick Squires, Santosh Gautam, Kaushal Desai, Monika Raut & Akash Nahar. (2022) Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin's lymphoma. Future Oncology 18:32, pages 3623-3636.
Crossref
Crossref
Surya K. De. 2022. Fundamentals of Cancer Detection, Treatment, and Prevention. Fundamentals of Cancer Detection, Treatment, and Prevention
67
131
.
Yu‐Chen Zhang, Jin‐Ni Wang, Shu‐Yun Ma, Jun Cai, Ning Su, Hui‐Qiang Huang, Zhi‐Ming Li, Zhong‐Jun Xia, He Huang, Pan‐Pan Liu, Yi Xia & Qing-Qing Cai. (2021)
Combination of PD‐1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin)
versus
GVD regimen as second‐line therapy for relapsed/refractory classical Hodgkin lymphoma
. British Journal of Haematology 196:1, pages 127-135.
Crossref
Crossref
Ahmet Sarici, Mehmet Ali Erkurt, Irfan Kuku, Selim Gok, Omer Faruk Bahcecioglu, Soykan Bicim, Ilhami Berber, Emin Kaya & Mustafa Ozgul. (2021) Selection of the mobilization regimen in lymphoma patients: A retrospective cohort study. Transfusion and Apheresis Science 60:5, pages 103251.
Crossref
Crossref
Gaurav Prakash, Arihant Jain, Kamalkant Sahu, Amanjit Bal, Charanpreet Singh, Rajender Basher, Harmandeep Singh, Kundan Mishra, Aditya Jandial, Deepesh Lad, Alka Khadwal, Radhika Srinivasan, Ashim Das, Neelam Varma, Subhash Varma & Pankaj Malhotra. (2021) Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience. BLOOD RESEARCH 56:3, pages 134-140.
Crossref
Crossref
Zoé Van de Wyngaert, Paul Coppo, Pascale Cervera, Bettina Fabiani, Marie‐Paule Lemonnier, Elise Corre, Zora Marjanovic, Malek Aoudjhane, Mohamad Mohty & Rémy Duléry. (2020) Combination of brentuximab‐vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T‐cell lymphoma. European Journal of Haematology 106:4, pages 467-472.
Crossref
Crossref
Timothy J Voorhees & Anne W Beaven. (2020) Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma. Cancers 12:10, pages 2887.
Crossref
Crossref
Richard T. HoppeRanjana H. AdvaniWeiyun Z. AiRichard F. AmbinderPhilippe ArmandCeleste M. BelloCecil M. BenitezPhilip J. BiermanKirsten M. BoughanBouthaina DabajaLeo I. GordonFrancisco J. Hernandez-IlizaliturriAlex F. HerreraEphraim P. HochbergJiayi HuangPatrick B. JohnstonMark S. KaminskiVaishalee P. KenkreNadia KhanRyan C. LynchKami MaddocksJonathan McConathyMatthew McKinneyMonika MetzgerDavid MorganCarolyn MulroneyRachel RabinovitchKaren C. RosenspireStuart SeropianRanda TaoJane N. WinterJoachim Yahalom, Jennifer L. BurnsNdiya Ogba. (2020) Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 18:6, pages 755-781.
Crossref
Crossref
Vishal Kulkarni, Sulav Sapkota, Girish V Badarkhe, BJ Srinivas & Radheshyam Naik. (2021) Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience. Indian Journal of Medical and Paediatric Oncology 41:01, pages 23-28.
Crossref
Crossref
Hailey Hill, Justin Arnall, Amanda Janes, Crystal Hatley, Kristen Swift, Christy Hargett, Theresa Howell, Sarah Griffin, Christopher Larck & Stephen Park. (2019) A review of R-DHAP administration in the outpatient setting and a case of the alternative regimen R-DHAX given outpatient for refractory diffuse large B-cell lymphoma. Journal of Oncology Pharmacy Practice 25:8, pages 2041-2044.
Crossref
Crossref
Frank Kroschinsky, Denise Röllig, Barbara Riemer, Michael Kramer, Rainer Ordemann, Johannes Schetelig, Martin Bornhäuser, Gerhard Ehninger & Mathias Hänel. (2019) Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas. Journal of Cancer Research and Clinical Oncology 145:12, pages 3067-3073.
Crossref
Crossref
Nikita Evgen'evich Mochkin, V.O. Sarzhevskii, Yu.N. Dubinina, E.G. Smirnova, D.A. Fedorenko, A.E. Bannikova, D.S. Kolesnikova, V.S. Bogatyrev, N.M. Faddeev & V.Ya. Mel'nichenko. (2018) Outcome of Classical Hodgkin’s Lymphoma Treatment Based on HighDose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery. Clinical oncohematology 11:3, pages 234-240.
Crossref
Crossref
Niloufer Khan & Alison J. Moskowitz. (2017) Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?. Current Hematologic Malignancy Reports 12:3, pages 227-233.
Crossref
Crossref
Jiangzheng Zeng, Liangxia Yang, Fen Huang, Tao Hong, Zhihui He, Junhua Lei, Huamao Sun, Yanda Lu & Xinbao Hao. (2016) The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin?s lymphoma. Cancer Chemotherapy and Pharmacology 78:4, pages 801-808.
Crossref
Crossref
Rakesh Raj, Pooja Mongia Raj & Alpana Ram. (2016) Preparation and characterization of solid lipid nanoparticles loaded with cytarabine via a micellar composition for leukemia. RSC Advances 6:58, pages 53578-53586.
Crossref
Crossref
Jan Maciej Zaucha, Andrzej Deptała & Renata Zaucha. (2016) Wczesna diagnostyka i leczenie postaci opornych i nawrotowych klasycznego chłoniaka Hodgkina. Acta Haematologica Polonica 47:1, pages 1-9.
Crossref
Crossref
Mojtaba Ghadiany, Mohammad Foratyazdi, Hossein Rahimi, Hamid Rezvani, Lila Sadeghi & Abbas Haji Fathali. (2013) Modified Irinotecan Plus Cisplatin and Dexamethasone (ICD) Combination Chemotherapy as Salvage Chemotherapy for Patients with Relapsed/Refractory Diffuse Large Cell Lymphoma. Indian Journal of Hematology and Blood Transfusion 30:4, pages 265-268.
Crossref
Crossref
Wei Xia, Chun Kei K Ma, Cassandra Reid, Lijun Bai, Kelly Wong, Ian Kerridge, Christopher Ward & Matthew Greenwood. (2014) Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation. Journal of Clinical Apheresis 29:6, pages 322-330.
Crossref
Crossref
Eliza A. Hawkes, Sarah Barton, David Cunningham, Clare Peckitt, Sue Chua, Andrew Wotherspoon, Alan Horwich, Mike Potter, Mark Ethel, Claire Dearden & Ian Chau. (2013) GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Annals of Hematology 93:5, pages 827-834.
Crossref
Crossref
Gi-Su OhHyung-Jin KimAiHua ShenSu Bin LeeDipendra KhadkaArpana PanditHong-Seob So. (2014) Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. Electrolytes & Blood Pressure 12:2, pages 55.
Crossref
Crossref
Maureen M. O’Brien, Michael J. Absalon, Thomas G. Gross & Kara M. Kelly. 2014. Hematopoietic Cell Transplantation in Children with Cancer. Hematopoietic Cell Transplantation in Children with Cancer
251
301
.
Anne W Beaven & David Rizzieri. (2012) Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. Clinical Investigation 2:1, pages 49-58.
Crossref
Crossref
Anna ColpoEphraim Hochberg & Yi‐Bin Chen. (2011) Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma. The Oncologist 17:1, pages 80-90.
Crossref
Crossref
Rebecca L. Elstrom, Peter Martin, Katya Ostrow, Jacqueline Barrientos, Amy Chadburn, Richard Furman, Jia Ruan, Tsiporah Shore, Michael Schuster, Leandro Cerchietti, Ari Melnick, Morton Coleman & John P. Leonard. (2010) Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. Clinical Lymphoma Myeloma and Leukemia 10:3, pages 192-196.
Crossref
Crossref
C. Fernández de Larrea, C. Martínez, A. Gaya, A. López-Guillermo, M. Rovira, F. Fernández-Avilés, M. Lozano, F. Bosch, J. Esteve, B. Nomdedeu, E. Montserrat & E. Carreras. (2010) Salvage chemotherapy with alternating MINE–ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Annals of Oncology 21:6, pages 1211-1216.
Crossref
Crossref
Assia L Angelova, Marc Aprahamian, Ginette Balboni, Henri-Jacques Delecluse, Regina Feederle, Irina Kiprianova, Svitlana P Grekova, Angel S Galabov, Mathias Witzens-Harig, Anthony D Ho, Jean Rommelaere & Zahari Raykov. (2009) Oncolytic Rat Parvovirus H-1PV, a Candidate for the Treatment of Human Lymphoma: In Vitro and In Vivo Studies. Molecular Therapy 17:7, pages 1164-1172.
Crossref
Crossref